Comparative Pharmacology
Head-to-head clinical analysis: DISOPHROL versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPHROL versus ZYRTEC.
DISOPHROL vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine